Cardiff Oncology, Inc. (CRDF)
0.9073
-0.02
(-2.23%)
USD |
NASDAQ |
Oct 23, 16:00
0.9006
-0.01
(-0.74%)
After-Hours: 20:00
Cardiff Oncology Enterprise Value : 28.09M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 28.09M |
| October 22, 2026 | 29.51M |
| October 21, 2026 | 30.26M |
| October 20, 2026 | 29.75M |
| October 19, 2026 | 26.61M |
| October 16, 2026 | 27.66M |
| October 15, 2026 | 32.45M |
| October 14, 2026 | 32.62M |
| October 13, 2026 | 35.12M |
| October 12, 2026 | 37.18M |
| October 09, 2026 | 39.92M |
| October 08, 2026 | 38.55M |
| October 07, 2026 | 40.60M |
| October 06, 2026 | 39.23M |
| October 05, 2026 | 44.03M |
| October 02, 2026 | 42.66M |
| October 01, 2026 | 46.77M |
| September 30, 2026 | 48.82M |
| September 29, 2026 | 46.08M |
| September 28, 2026 | 48.14M |
| September 25, 2026 | 50.88M |
| September 24, 2026 | 53.62M |
| September 23, 2026 | 55.67M |
| September 22, 2026 | 57.04M |
| September 21, 2026 | 59.78M |
| Date | Value |
|---|---|
| September 18, 2026 | 59.78M |
| September 17, 2026 | 54.99M |
| September 16, 2026 | 58.41M |
| September 15, 2026 | 57.73M |
| September 14, 2026 | 55.67M |
| September 11, 2026 | 48.82M |
| September 10, 2026 | 48.82M |
| September 09, 2026 | 37.86M |
| September 08, 2026 | 41.29M |
| September 04, 2026 | 40.60M |
| September 03, 2026 | 39.92M |
| September 02, 2026 | 38.55M |
| September 01, 2026 | 36.49M |
| August 31, 2026 | 34.00M |
| August 28, 2026 | 30.33M |
| August 27, 2026 | 33.49M |
| August 26, 2026 | 33.35M |
| August 25, 2026 | 35.81M |
| August 24, 2026 | 34.30M |
| August 21, 2026 | 26.23M |
| August 20, 2026 | 28.18M |
| August 19, 2026 | 27.44M |
| August 18, 2026 | 26.64M |
| August 17, 2026 | 27.88M |
| August 14, 2026 | 31.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.232M |
| Revenue (Quarterly) | 0.104M |
| Total Expenses (Quarterly) | 9.336M |
| EPS Diluted (Quarterly) | -0.1351 |
| Gross Profit Margin (Quarterly) | -113.5% |
| Profit Margin (Quarterly) | -8.88K% |
| Earnings Yield | -65.09% |
| Normalized Earnings Yield | -65.08 |